| 16.35 0.04 (0.25%) | 10-09 15:36 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.41 | 1-year : | 26.17 |
| Resists | First : | 19.19 | Second : | 22.41 |
| Pivot price | 16.6  |
|||
| Supports | First : | 14.6 | Second : | 11.76 |
| MAs | MA(5) : | 16.77 |
MA(20) : | 15.62 |
| MA(100) : | 11.47 |
MA(250) : | 9.19 |
|
| MACD | MACD : | 1 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 57.9 |
D(3) : | 64.4 |
| RSI | RSI(14): 55.6 |
|||
| 52-week | High : | 19.19 | Low : | 2.3 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ COEP ] has closed above bottom band by 39.3%. Bollinger Bands are 8.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.01 - 17.12 | 17.12 - 17.22 |
| Low: | 16.07 - 16.17 | 16.17 - 16.26 |
| Close: | 16.15 - 16.33 | 16.33 - 16.47 |
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Sun, 05 Oct 2025
Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Decreases By 35.3% - MarketBeat
Tue, 30 Sep 2025
Coeptis Therapeutics (NASDAQ:COEP) Stock Price Down 5.7% - Should You Sell? - MarketBeat
Tue, 23 Sep 2025
Coeptis Therapeutics Implements Innovative Dual-Track Model to Drive Revenue and Research Efficiency - Quiver Quantitative
Tue, 23 Sep 2025
$44.39B Cell Therapy Market by 2034: Coeptis Pioneers Hybrid Revenue Model While Advancing Cancer Research - Stock Titan
Tue, 22 Jul 2025
Coeptis Therapeutics Holdings, Inc. Announces Extinguishment of Convertible Note, Strengthening Capital Structure - Nasdaq
Wed, 18 Jun 2025
Coeptis Therapeutics Holdings (NASDAQ:COEP) Has Debt But No Earnings; Should You Worry? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 4.2e+006 (%) |
| Held by Institutions | 13.3 (%) |
| Shares Short | 59 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.179e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 252.9 % |
| Return on Equity (ttm) | -98.3 % |
| Qtrly Rev. Growth | 263560 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.7 |
| Qtrly Earnings Growth | -6.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.44 |
| Dividend | 0 |
| Forward Dividend | 41200 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|